Details for: CL2000095

Cell ID: CL2000095

Cell Name: cord blood hematopoietic stem cell

Description: Any hematopoietic stem cell that is part of a umbilical cord blood.

Selected Context(s): Overall

Gene Significance Landscape

Display Options
Score:
Display
Genes

Contexts:

Cell Significance Index (CSI) is uniquely calculated to reveal cell-specific gene markers. More info here

Significant Genes List

Genes with the highest and lowest Percentile Rank Scores (PRS) for cord blood hematopoietic stem cell within the selected context(s).

Gene ID: A unique numerical identifier for this specific gene.
Symbol: Shortened abbreviation or name that represents this gene.
Ensembl Gene ID: A unique identifier assigned by Ensembl for genomic data mapping.
CSI Score: A combined effect size and statistical significance measure for cord blood hematopoietic stem cell. Higher scores indicate a stronger, more significant difference in expression.
(Previously described as "Fold Change", but now represents Cliff's Delta × –log10(p).)

Gene ID: A unique numerical identifier for this specific gene.
Symbol: Shortened abbreviation or name that represents this gene.
Ensembl Gene ID: A unique identifier assigned by Ensembl for genomic data mapping.
CSI Score: A combined effect size and statistical significance measure for cord blood hematopoietic stem cell. Higher scores indicate a stronger, more significant difference in expression.
Average CSI: csi sum / gene count
Cell network configuration

This network visualizes key genes for cord blood hematopoietic stem cell. It primarily includes:
1. Top genes highly significant for this cell (Num. Top Cell Genes - based on the 'Min. CSI' setting).
2. Any additional specific 'Context Genes' you add below.
The final network is a combined view. Choose an Interaction Source (pathways or protein interactions) and optionally compare CSI scores with a Baseline Cell Type.

Maximum number of selected genes.
Select a context for the baseline cell.
Select a context for the target cell.
Target Cell for CSI:  cord blood hematopoietic stem cell (CL2000095)

 Legend
Nodes (Genes):
 Query Gene
Node size also reflects Target Cell CSI magnitude.
Node Color (Target Cell CSI in specific network):
 Very High
 High
 Medium
 Low
 Very Low
 N/A or Not Sig.
Edges (Interactions):
 STRING (Protein-Protein)
 ONTOLOGY (Shared Pathway)
 Colors vary by pathway category; default arrow applies.

Loading network (please wait)...

## Summary The [cord blood hematopoietic stem cell](/details-cell/CL2000095) is a multipotent progenitor cell responsible for reconstituting the blood and immune systems. Based on its gene significance profile, this cell type is characterized by a high state of readiness for protein synthesis, a robust defense against oxidative stress, and priming towards an early lymphoid lineage. **Overall**, the specific expression of genes like the antioxidant enzyme [`GPX1`](/details-gene/2876), the pre-B cell marker [`IGLL1`](/details-gene/3543), and numerous ribosomal protein-related transcripts suggests a cell metabolically poised for quiescence but transcriptionally prepared for rapid proliferation and differentiation, particularly along the lymphoid developmental pathway. ## Key Characteristics and Function The molecular signature of the [cord blood hematopoietic stem cell](/details-cell/CL2000095) is defined by several key functional clusters. * **High Translational Potential:** A striking feature is the high expression specificity (`csi_z`) for numerous ribosomal protein genes and pseudogenes, including [`RPL7P9`](/details-gene/653702), [`RPL36AP37`](/details-gene/729362), and [`RPL18AP3`](/details-gene/390354). This is further supported by the specific expression of [`MAGOH`](/details-gene/4116), a core component of the exon junction complex involved in mRNA processing. This collective signature indicates that these stem cells possess a pre-established and robust machinery for protein synthesis, likely enabling rapid activation, proliferation, and differentiation upon receiving appropriate signals. * **Immune and Lymphoid Priming:** The high specificity of [`IGLL1`](/details-gene/3543), a gene associated with pre-B cell receptor complexes ([Link](https://doi.org/10.1073/pnas.86.14.5552)), strongly suggests that these hematopoietic stem cells (HSCs) are primed for or contain a subpopulation biased towards the B-lymphoid lineage. The presence of [`CD69`](/details-gene/969), a canonical early activation antigen for lymphocytes ([Link](https://pubmed.ncbi.nlm.nih.gov/8340758/)), as a defining marker further supports the notion of a cell population poised for immune differentiation and activation. Additionally, significant expression of [`LCP1`](/details-gene/3936) (Plastin-2), an actin-bundling protein essential for hematopoietic cell motility and immune synapse formation, and [`AIF1`](/details-gene/199), an inflammatory response factor, highlights the inherent immune potential of this cell type. * **Oxidative Stress Management:** The glutathione peroxidase gene [`GPX1`](/details-gene/2876) is one of the most specific markers for this cell type. This suggests that the management of reactive oxygen species (ROS) is a critical and defining function, which is consistent with the need to protect the genomic integrity and maintain the long-term repopulating capacity of the stem cell pool. * **Metabolic Profile:** The anti-marker profile provides strong evidence for the metabolic state of these cells. There is a significant negative association with numerous genes essential for oxidative phosphorylation, including components of the cytochrome c oxidase complex ([`COX8A`](/details-gene/1351), [`COX7A2`](/details-gene/1347), [`COX4I1`](/details-gene/1327)) and NADH:ubiquinone oxidoreductase ([`NDUFA4`](/details-gene/4697)). This signature is characteristic of stem cells that rely primarily on glycolysis rather than mitochondrial respiration, a state believed to minimize ROS production and maintain stemness. The low specificity of pro-inflammatory mediators like [`HMGB1`](/details-gene/3146) and [`MIF`](/details-gene/4282) further reinforces their non-activated, homeostatic state. ## Clinical Significance and Contextual Roles **Overall**, cord blood hematopoietic stem cells are a critical resource for allogeneic hematopoietic stem cell transplantation, used to treat a variety of hematological malignancies, bone marrow failure syndromes, and genetic disorders. The molecular profile presented here offers insights into their clinical behavior. The pronounced expression of ribosomal machinery is consistent with the high proliferative potential required for successful engraftment and hematopoietic reconstitution in a recipient. The specific signature of lymphoid-priming genes like [`IGLL1`](/details-gene/3543) may correlate with the clinical observation that cord blood transplants can lead to rapid lymphoid recovery. Furthermore, the robust antioxidant program, highlighted by [`GPX1`](/details-gene/2876), likely contributes to the viability and functional integrity of these cells during the cryopreservation and thawing processes inherent to cord blood banking and transplantation. The relative immune immaturity, suggested by the low expression of potent inflammatory mediators, may contribute to the lower incidence and severity of graft-versus-host disease (GVHD) associated with cord blood transplantation compared to other stem cell sources. ## Potential Mechanisms and Research Directions 1. **Hypothesis: Cord blood HSCs are pre-committed to a lymphoid fate.** The highly specific expression of the pre-B cell marker [`IGLL1`](/details-gene/3543) and the early lymphocyte activation marker [`CD69`](/details-gene/969) suggests that a subset of cells within the cord blood HSC pool is not truly multipotent but is already epigenetically and transcriptionally biased toward a lymphoid lineage. This pre-commitment could provide a developmental shortcut, enabling faster reconstitution of the adaptive immune system post-transplantation. * **Surprising Findings:** The identification of [`CD69`](/details-gene/969), traditionally viewed as a marker of recent activation on mature lymphocytes, as a defining specific marker for a supposedly quiescent stem cell population is unexpected. This challenges the conventional view of HSCs and suggests a state of "poised activation." * **Testable Questions:** Does a distinct subpopulation of CD34+ cord blood cells co-express surface [`CD69`](/details-gene/969) protein and [`IGLL1`](/details-gene/3543) transcripts? If so, does this subpopulation exhibit a higher propensity for in vitro B-cell differentiation and show a unique epigenetic signature at key lymphoid developmental loci compared to its [`CD69`](/details-gene/969)-negative counterparts? 2. **Hypothesis: The metabolic state of cord blood HSCs is actively maintained by antioxidant defense rather than solely by low metabolic activity.** The data reveals a dual signature: a strong negative association with oxidative phosphorylation machinery and a highly specific positive association with the antioxidant enzyme [`GPX1`](/details-gene/2876). This suggests that the low-ROS environment critical for stemness is not a passive consequence of glycolysis but is actively enforced by a robust ROS-scavenging system. This [`GPX1`](/details-gene/2876)-dependent mechanism may be essential for protecting the cells from both endogenous metabolic byproducts and exogenous stressors. * **Surprising Findings:** The expression specificity of [`GPX1`](/details-gene/2876) (PRS: 95.0%) rivals or exceeds that of many established stem or progenitor markers, proposing that antioxidant capacity is a primary, rather than secondary, defining feature of this cell's identity. * **Testable Questions:** Does shRNA-mediated knockdown of [`GPX1`](/details-gene/2876) in cord blood HSCs lead to increased intracellular ROS, activation of DNA damage pathways, and a loss of long-term repopulating potential in xenotransplant models? Furthermore, does [`GPX1`](/details-gene/2876) inhibition force a metabolic shift away from glycolysis and towards oxidative phosphorylation as a compensatory mechanism?